Free tool
FAERS Monitor: Carafate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018333 or its brand name (Carafate, Sucralfate). Reports on generic versions are filed under their own applications.
Reports
24,155
Serious
16,587
69% of reports
Hospitalization
9,364
Death reported
2,328
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea2,389
- fatigue1,831
- diarrhoea1,787
- pain1,543
- headache1,453
- vomiting1,433
- off label use1,386
- dyspnoea1,383
- drug ineffective1,359
- dizziness1,095
- abdominal pain1,035
- weight decreased1,031
- malaise1,013
- pneumonia991
- chronic kidney disease988
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 252 |
| 2005 | 266 |
| 2006 | 251 |
| 2007 | 265 |
| 2008 | 324 |
| 2009 | 405 |
| 2010 | 543 |
| 2011 | 660 |
| 2012 | 880 |
| 2013 | 727 |
| 2014 | 841 |
| 2015 | 1,422 |
| 2016 | 1,829 |
| 2017 | 1,577 |
| 2018 | 1,878 |
| 2019 | 2,058 |
| 2020 | 1,851 |
| 2021 | 1,461 |
| 2022 | 1,358 |
| 2023 | 1,407 |
| 2024 | 1,322 |
| 2025 | 1,509 |
| 2026 | 1,064 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,004 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 988 | 11.5 | 10.8 | 9,332 |
| abdominal painSignal | 1,035 | 3.9 | 3.7 | 2,231 |
| weight decreasedSignal | 1,031 | 3.2 | 3.0 | 1,595 |
| pneumoniaSignal | 991 | 2.7 | 2.5 | 1,047 |
| vomitingSignal | 1,433 | 2.7 | 2.5 | 1,511 |
| nauseaSignal | 2,389 | 2.6 | 2.5 | 2,505 |
| diarrhoeaSignal | 1,787 | 2.4 | 2.3 | 1,522 |
| painSignal | 1,543 | 2.2 | 2.1 | 1,024 |
| dyspnoeaSignal | 1,383 | 2.1 | 2.0 | 849 |
| fatigueSignal | 1,831 | 2.1 | 2.0 | 1,020 |
| headacheSignal | 1,453 | 2.0 | 1.9 | 769 |
| malaiseSignal | 1,013 | 2.0 | 1.9 | 526 |
| dizziness | 1,095 | 1.9 | 1.8 | 487 |
| off label use | 1,386 | 1.4 | 1.3 | 150 |
| drug ineffective | 1,359 | 0.9 | 0.9 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.